Results 111 to 120 of about 53,113 (297)

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab

, 2022
Kei Endo, Hidekatsu Kuroda, Takayoshi Oikawa, Yuma Ito, Tamami Abe, Youhei Kooka, Keisuke Kakisaka, Akio Miyasaka, Tamotsu Sugai, Takayuki Matsumoto   +9 more
openalex   +1 more source

Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study [PDF]

, 2023
Yanjun Xu, Zhiyu Huang, Jianhua Chang, Yan Yu, Chunling Liu, Juan Li, Jing Zhao, Dongqing Lv, Si Sun, Qiannan Zhang, Yi Zhou, Jiahui Xu, Yun Fan   +12 more
openalex   +1 more source

Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology

Med Research, EarlyView.
The graphical abstract outlines the progressive development and impact of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Technological Evolution illustrates the transition from brachytherapy with single‐dose, LDR/HDR schedules to fractionated radiotherapy, three‐dimensional conformal radiotherapy (3DCRT) and Gamma Knife ...
Jing Zhang, Wenhao Xu, Weiqing Lu, Yingxuan Lin, Luoxi He, Zonglin Lv, Yiliyaer Nuerrula, Zouting, Zhen Zhang, Hailiang Zhang, Xuejun Ma   +10 more
wiley   +1 more source

The Evolution of Pneumocystis jirovecii Pneumonia Prophylaxis for Pediatric Patients With Extracranial Solid Tumors: A Review of Historical Insights and Future Directions

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a modern‐day complication for pediatric patients receiving treatment for extracranial solid tumors (ST), highlighting the need for reconsideration of our current approach toward PJP prophylaxis. This critical review aims to evaluate both universal and risk‐stratified approaches to PJP prophylaxis ...
Kriti Kumar, Denise M. Connolly, Ellen Kellington, Elyse Zelunka, Karla Kerrigan, Furqan Shaikh, Paul C. Nathan, Meredith S. Irwin, Sarah Cohen‐Gogo   +8 more
wiley   +1 more source

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, EarlyView.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source

Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial [PDF]

, 2023
Simon J. Crabb, Robin Wickens, Sarah Jane-Bibby, Denise Dunkley, Megan Lawrence, Allen Knight, Robert J. Jones, Alison Birtle, Robert Huddart, Mark Linch, Jonathan Martin, Adam Coleman, Konstantinos Boukas, Hannah Markham, Gareth Griffiths   +14 more
openalex   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab

, 2023
Chiara Colarusso, Anna Falanga, Michela Terlizzi, Ilaria De Rosa, Pasquale Somma, Eduardo Sommella, Vicky Caponigro, Luigi Panico, Emanuela Salviati, Pietro Campiglia, Giuseppe Salatiello, Teresa Tramontano, Piera Maiolino, Aldo Pinto, Rosalinda Sorrentino   +14 more
openalex   +1 more source

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study [PDF]

, 2022
Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon, Hong Jae Chon   +8 more
openalex   +1 more source

Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Are two drugs better than one in advanced NSCLC? ABSTRACT Background Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand‐1 (PD‐L1) ≥ 50% advanced non–small cell lung cancer (NSCLC).
Junipearl Cheng, Charlotte McKay, Victoria Bray, Po Yee Yip, Annette Tognela, Peey Sei Kok   +5 more
wiley   +1 more source